William Blair Issues Optimistic Forecast for KROS Earnings

Keros Therapeutics, Inc. (NASDAQ:KROS) – Research analysts at William Blair lifted their Q2 2025 earnings estimates for Keros Therapeutics in a report issued on Tuesday, December 3rd. William Blair analyst M. Phipps now expects that the company will post earnings per share of ($1.04) for the quarter, up from their prior forecast of ($1.18). The consensus estimate for Keros Therapeutics’ current full-year earnings is ($5.28) per share. William Blair also issued estimates for Keros Therapeutics’ Q3 2025 earnings at ($0.79) EPS, Q4 2025 earnings at ($0.58) EPS, FY2025 earnings at ($3.65) EPS, FY2026 earnings at ($2.91) EPS and FY2027 earnings at ($2.65) EPS.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The business had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm’s revenue for the quarter was up 4750.0% on a year-over-year basis. During the same period last year, the company posted ($1.33) EPS.

KROS has been the subject of a number of other research reports. Scotiabank started coverage on shares of Keros Therapeutics in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 target price for the company. HC Wainwright reiterated a “buy” rating and issued a $100.00 target price on shares of Keros Therapeutics in a research note on Thursday, November 7th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Keros Therapeutics in a research note on Friday, November 22nd. Jefferies Financial Group started coverage on shares of Keros Therapeutics in a research note on Tuesday, November 5th. They issued a “buy” rating for the company. Finally, Guggenheim reiterated a “buy” rating and issued a $102.00 target price (up previously from $96.00) on shares of Keros Therapeutics in a research note on Wednesday. Twelve equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $89.56.

Keros Therapeutics Trading Down 4.7 %

NASDAQ:KROS opened at $64.61 on Thursday. Keros Therapeutics has a 1 year low of $27.31 and a 1 year high of $73.00. The firm has a 50 day moving average of $60.05 and a 200-day moving average of $52.56. The stock has a market capitalization of $2.62 billion, a P/E ratio of -12.40 and a beta of 1.20.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of KROS. KBC Group NV grew its holdings in Keros Therapeutics by 52.0% during the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after acquiring an additional 432 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in Keros Therapeutics by 26.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after acquiring an additional 280 shares during the period. Values First Advisors Inc. acquired a new stake in Keros Therapeutics during the 3rd quarter worth $89,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Keros Therapeutics during the 2nd quarter worth $128,000. Finally, LMR Partners LLP acquired a new stake in Keros Therapeutics during the 3rd quarter worth $213,000. Institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.